AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

838.945

+6.8160.82%

Number of Gainers:13

Number of Losers:7

Number of Flat:25

PE:- -

High:843.382

Open:828.860

Low:828.659

Close:832.129

Loading ...

Cann Group Ltd - Qtrly Production of 1.53 Tonnes

THOMSON REUTERS

CSL Unit, US Partner Say European Commission Grants Marketing Authorization for Kidney Disease Treatment Drug

MT Newswires Live

Press Release: Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

CSL Unit Awarded Contract by EU Regulator to Reserve 27 Million Flu Vaccine Doses

MT Newswires Live

Orthocell Ltd - Remplir Approved to Commence Sales in Canadian Market

THOMSON REUTERS

How to turn $100 a week into $500,000 with ASX shares

ASX Growth Stocks With High Insider Ownership

Simply Wall St.

Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy

MT Newswires Live

BRIEF-Csl Seqirus Signs Agreement With The European Commission To Support Pandemic Preparedness Plans

CSL Ltd - CSL Seqirus Signs Agreement With the European Commission to Support Pandemic Preparedness Plans

THOMSON REUTERS

Brokers tip 4 ASX 200 healthcare shares to buy now

BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy

CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy

THOMSON REUTERS

Immutep Posts AU$92.5 Million Cash Balance in March Quarter

MT Newswires Live

Orthocell Ltd - Requests Trading Halt Pending Announcement on New Regulatory Approval for Remplir

THOMSON REUTERS

BRIEF-Dimerix Seeks Trading Halt

BRIEF-Orthocell Seeks Trading Halt

Orthocell Ltd - Seeks Trading Halt Pending Announcement on New Regulatory Approval for Remplir

THOMSON REUTERS

Mesoblast Appoints Corporate Finance Leader Lyn Cobley to Board

THOMSON REUTERS

Press Release: Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":838.9448,"timestamp":1746152195849,"preClose":832.1293,"halted":0,"volume":30892973,"delay":0,"changeRate":0.00819,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":6.815552,"latestTime":"05-02 12:16:36 AEST","open":828.86017,"high":843.382,"low":828.659,"amount":134236266,"amplitude":0.017693,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746165600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746144000000,1746165600000]],"turnoverRate":0.000856,"increases":14,"decrements":7,"flats":22,"marketCap":133706846985.375,"floatMarketCap":130881146094},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":843.382,"amplitude":0.017693,"preClose":832.1293,"low":828.659,"latestPrice":838.9448,"volume":30892973,"delay":0,"open":828.86017,"prevYearClose":936.801,"prevWeekClose":799.528,"prevMonthClose":827.414,"prevQuarterClose":815.605,"fiveDayClose":799.528,"twentyDayClose":818.605,"sixtyDayClose":916.519,"secType":"PLATE","market":"AU","turnoverRate":0.000856,"marketCap":133706846985.375,"floatMarketCap":130881146094,"timestamp":1746152195849,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":13,"down":7,"flat":25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531813741","title":"Cann Group Ltd - Qtrly  Production of 1.53 Tonnes","url":"https://stock-news.laohu8.com/highlight/detail?id=2531813741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531813741?lang=en_us&edition=fundamental","pubTime":"2025-04-30 09:19","pubTimestamp":1745975944,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R802T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","BK7502","CAN.AU"],"gpt_icon":0},{"id":"2531774643","title":"CSL Unit, US Partner Say European Commission Grants Marketing Authorization for Kidney Disease Treatment Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2531774643","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531774643?lang=en_us&edition=fundamental","pubTime":"2025-04-30 08:57","pubTimestamp":1745974653,"startTime":"0","endTime":"0","summary":"CSL's  Switzerland-based pharmaceutical unit, CSL Vifor, and US biopharmaceutical firm Travere Therapeutics said the European Commission has granted standard marketing authorization for Filspari, a treatment for primary IgA nephropathy , a rare and progressive kidney disease, according to a Tuesday statement by the company.The decision converts a previous conditional marketing authorization and extends to all European Union member states, as well as Iceland, Liechtenstein, and Norway, the company said.Filspari was developed by Travere Therapeutics and exclusively licensed to CSL Vifor for commercialization in Europe, Australia, and New Zealand.CSL's shares rose 1% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","CSL","CSL.AU","LU0728928796.USD","BK4086","SG9999004303.SGD","LU1169589451.USD","LU1169590202.USD","BK7511","BK7501","SGXZ23171101.USD","BK7508"],"gpt_icon":0},{"id":"2531746982","title":"Press Release: Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531746982","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531746982?lang=en_us&edition=fundamental","pubTime":"2025-04-30 08:53","pubTimestamp":1745974380,"startTime":"0","endTime":"0","summary":"NEW YORK, April 29, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025.\"We were very pleased to have made Ryoncil  commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell  therapy approved in the US for any indication,\" said Dr. Silviu Itescu, CEO of Mesoblast. \"With our strong cash position we are well placed to expand Ryoncil indications to other serious and life-threatening pediatric inflammatory diseases, and to adults with acute GvHD.\". -- Net operating cash spend for the quarter was US$12.7 million.-- Cash on hand at the end of the quarter was US$182 million (A$290. -- Ryoncil became commercially available for purchase in the United. States on March 28, 2025, with Federal Medicaid coverage, and to date 15. infusion kits have been purchased for patients t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4141","BK4099","IE00BHPRN162.USD","IE00BKVL7J92.USD","BK4585","MSB","BK4170","LU1363072403.SGD","CMC","BK4526","MESO","BK4543","ASX","BK7067","MSB.AU","BK7508","R","BK4555","IE00B1BXHZ80.USD","LU0971096721.USD","BK4161","TM","LU0149725797.USD","BK4022","LU0267386448.USD","BK4546","BK7501","BK4604","BK4551","BK4575","DDD","BK4150","LU0170899867.USD","LU0882574139.USD","MSC","03160","IE00BZ1G4Q59.USD","BK4139","BK4588","BK4232"],"gpt_icon":0},{"id":"2531774308","title":"CSL Unit Awarded Contract by EU Regulator to Reserve 27 Million Flu Vaccine Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2531774308","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531774308?lang=en_us&edition=fundamental","pubTime":"2025-04-30 08:31","pubTimestamp":1745973088,"startTime":"0","endTime":"0","summary":"CSL  said Tuesday CSL Seqirus was awarded a contract by the Health Emergency Preparedness and Response Authority to support the pandemic preparedness plans of 17 European Union and European Economic Area member states as well as the European Commission.Under the contract, 27 million doses of pandemic influenza vaccine have been reserved with CSL Seqirus, which can be ordered by the participating countries in the event of an influenza pandemic, according to a statement.The deal requires CSL Seqirus to be prepared to rapidly manufacture and deliver these vaccine doses. The doses will be produced at the company's manufacturing site in Liverpool, UK.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4086","BK7067","CSL","BK7508","CSL.AU","BK7511","LU1169589451.USD","LU0728928796.USD","LU1169590202.USD","SG9999004303.SGD","SGXZ23171101.USD","BK4156","BK7501"],"gpt_icon":0},{"id":"2531714044","title":"Orthocell Ltd -  Remplir Approved to Commence Sales in Canadian Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2531714044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531714044?lang=en_us&edition=fundamental","pubTime":"2025-04-30 07:08","pubTimestamp":1745968135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R725A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2531071038","title":"How to turn $100 a week into $500,000 with ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2531071038","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531071038?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:15","pubTimestamp":1745964914,"startTime":"0","endTime":"0","summary":"Investing can seem daunting at first — especially if you're starting small. But here's the good news: you don't need a huge salary, a stock-picking superpower, or perfect timing to build serious wealt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/30/how-to-turn-100-a-week-into-500000-with-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CSL.AU","WES.AU","BK7508","WTC.AU","BK7501","BK7041","BK7503","BK7007","BK7511","RMD.AU","BK7153","BK7016","IVV.AU","BK7067","VGS.AU"],"gpt_icon":0},{"id":"2531998837","title":"ASX Growth Stocks With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2531998837","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531998837?lang=en_us&edition=fundamental","pubTime":"2025-04-30 03:38","pubTimestamp":1745955480,"startTime":"0","endTime":"0","summary":"The Australian market has recently shown positive momentum, with the ASX200 closing up 0.92% at 8,070 points, driven by strong performances in sectors like Energy and Utilities. In this environment of growth and sectoral strength, identifying stocks with high insider ownership can be particularly appealing as it often suggests confidence from those who know the company best.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 96 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Guzman y Gomez Limited's recent sales figures show strong growth, with Q1 2025 network sales reaching A$289.5 million, up from A$234.2 million the previous year. The company has transitioned to profitability, reporting a net income of A$7.3 million for H1 2024-25 compared to a loss previously. Despite substantial insider selling over the past three months, revenue is fore","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-stocks-high-insider-193800414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["EIQ.AU","AAL.AU","IMA.AU","NWF.AU","TTT.AU","PYC.AU","ACR.AU","BK7007","BK7067","BK7137","XAO.AU","BK7036","GYG.AU","BK7093","BK7016","BK7508","PLT.AU","DVP.AU","FEX.AU","BK7129","XJO.AU","CYC.AU","BK7095","XKO.AU","BK7116","BK7078","BBT.AU","BK7077","BK7096"],"gpt_icon":0},{"id":"2531512517","title":"Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531512517","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531512517?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:51","pubTimestamp":1745938294,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) and CSL Vifor said Tuesday that the European Commission has converted the conditional marketing approval of Filspari into a standard marketing authorization for the treatme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4156","SGXZ23171101.USD","TVTX","BK4086","BK7508","BK7511","LU1169589451.USD","LU1169590202.USD","CSL.AU","SG9999004303.SGD","CSL","LU0728928796.USD","BK4139","BK7501","BK7067"],"gpt_icon":0},{"id":"2531769785","title":"BRIEF-Csl Seqirus Signs Agreement With The European Commission To Support Pandemic Preparedness Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2531769785","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531769785?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:58","pubTimestamp":1745924321,"startTime":"0","endTime":"0","summary":"BRIEF-Csl Seqirus Signs Agreement With The European Commission To Support Pandemic Preparedness PlansApril 29  - CSL Ltd CSL.AX:CSL SEQIRUS SIGNS  AGREEMENT WITH THE EUROPEAN COMMISSION TO SUPPORT PANDEMIC PREPAREDNESS PLANSFurther company coverage: CSL.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R70YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7511","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2531120074","title":"CSL Ltd - CSL Seqirus Signs  Agreement With the European Commission to Support Pandemic Preparedness Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2531120074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531120074?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:30","pubTimestamp":1745922653,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R70YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","CSL.AU","BK7501","BK7511"],"gpt_icon":0},{"id":"2531227449","title":"Brokers tip 4 ASX 200 healthcare shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2531227449","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531227449?lang=en_us&edition=fundamental","pubTime":"2025-04-29 15:05","pubTimestamp":1745910347,"startTime":"0","endTime":"0","summary":"ASX 200 healthcare shares finished in the green on Tuesday, with the S&P/ASX 200 Health Care Index  lifting 0.61%.  Healthcare is seen as a defensive sector.  In today's turbulent market, perhaps you might be looking for buying opportunities?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/brokers-tip-4-asx-200-healthcare-shares-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","TLX.AU","BK7511","HLS.AU","CSL.AU","BK7067","RMD.AU","BK7124","BK7501","BK7509","BK7007"],"gpt_icon":0},{"id":"2531225933","title":"BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531225933","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531225933?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:04","pubTimestamp":1745906694,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari In Iga NephropathyApril 29 (Reuters) - CSL Ltd CSL.AX:CSL VIFOR AND TRAVERE THERAPEUTICS ANNOUNCE STANDARD EU APPROV","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7067","CSL.AU","BK4139","BK7501","TVTX"],"gpt_icon":0},{"id":"2531225879","title":"CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531225879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531225879?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:01","pubTimestamp":1745906478,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CSL.AU","BK7508","BK4139","BK7501","BK7511","TVTX"],"gpt_icon":0},{"id":"2531921273","title":"Immutep Posts AU$92.5 Million Cash Balance in March Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2531921273","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531921273?lang=en_us&edition=fundamental","pubTime":"2025-04-29 10:37","pubTimestamp":1745894241,"startTime":"0","endTime":"0","summary":"Immutep  ended the fiscal third quarter with a cash balance of AU$92.5 million, according to a Tuesday filing with the Australian bourse.It also has short-term bank deposits of AU$53.8 million, the filing said.The clinical-stage biotechnology company saw progress in its ongoing trials during the quarter. This year, it expects analysis and safety assessment reports for treatments of breast cancer and autoimmune disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2531216094","title":"Orthocell Ltd - Requests Trading Halt Pending Announcement on New Regulatory Approval for Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2531216094","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531216094?lang=en_us&edition=fundamental","pubTime":"2025-04-29 09:53","pubTimestamp":1745891624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OCC.AU","BK7508"],"gpt_icon":0},{"id":"2531319216","title":"BRIEF-Dimerix Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2531319216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531319216?lang=en_us&edition=fundamental","pubTime":"2025-04-29 09:44","pubTimestamp":1745891050,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Seeks Trading HaltApril 29 (Reuters) - Dimerix Ltd DXB.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON LICENSING AGREEMENTFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2531213113","title":"BRIEF-Orthocell Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2531213113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531213113?lang=en_us&edition=fundamental","pubTime":"2025-04-29 09:26","pubTimestamp":1745889965,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Seeks Trading Halt April 29 (Reuters) - Orthocell OCC.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON  NEW REGULATORY APPROVAL FOR REMPLIRFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2531370213","title":"Orthocell Ltd - Seeks Trading Halt Pending Announcement on  New Regulatory Approval for Remplir","url":"https://stock-news.laohu8.com/highlight/detail?id=2531370213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531370213?lang=en_us&edition=fundamental","pubTime":"2025-04-29 09:23","pubTimestamp":1745889805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OCC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2531429967","title":"Mesoblast Appoints Corporate Finance Leader Lyn Cobley to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2531429967","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531429967?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:44","pubTimestamp":1745883858,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nTUA6QPWHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MSB.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2531299972","title":"Press Release: Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2531299972","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531299972?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:44","pubTimestamp":1745883840,"startTime":"0","endTime":"0","summary":"NEW YORK, April 28, 2025  -- Mesoblast , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited.Commenting on her appointment Ms. Cobley said, \"Following the recent United States Food and Drug Administration  approval of Ryoncil , Mesoblast has become a wonderful success story for not only the Australian biotechnology industry but the global leader in the allogeneic cell therapy industry. The Company has many exciting milestones in the near-term including ramp-up of commercialization and additional indications for some highly prevalent diseases. I look forward to co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK4232","BK7508","BK4022","MSB.AU","R","BK4006","MSC","BK4139","BK7067","BK4575","MSB","BK4150","MESO"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":100,"code":"91000000","status":"200"}]}}